FDA proposals include ‘major updates’ to simplify biosimilarity studies, reduce unnecessary clinical testing, and ease the process for making biosimilars interchangeable with brand-name biologics.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-aims-streamline-biosimilar-drug-development-2025a1000whe?src=rss
Author :
Publish date : 2025-11-21 11:31:00
Copyright for syndicated content belongs to the linked Source.
